Michael Siem

March 22, 2019 | New York Law Journal

Since the Hatch-Waxman Act has been in effect, there has been an increase in the number of challenges to patents covering chemical compounds. With the advent of inter partes reviews, the expectation was that there would be an uptick in compound claims being found obvious due to the expertise of the Patent Trial and Appeal Board. That has not been the case. Instead, as outlined here, the exact opposite has happened.

By Debra Doby and Michael Siem

8 minute read